Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C. Moretto R, et al. Among authors: pella n. Br J Cancer. 2022 Sep;127(5):957-967. doi: 10.1038/s41416-022-01852-0. Epub 2022 Jun 3. Br J Cancer. 2022. PMID: 35665778 Free PMC article.
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Guglielmi A, Barni S, Zaniboni A, Pella N, Belvedere O, Beretta GD, Grossi F, Frontini L, Puglisi F, Labianca R, Sobrero A; Gruppo Italiano Studio Carcinomi Apparato Digerente. Guglielmi A, et al. Among authors: pella n. Br J Cancer. 2004 Oct 18;91(8):1428-33. doi: 10.1038/sj.bjc.6602176. Br J Cancer. 2004. PMID: 15381935 Free PMC article. Clinical Trial.
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7. Pharmacogenomics J. 2013. PMID: 22868256 Free PMC article.
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21. Pharmacogenomics J. 2015. PMID: 25331073
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S, Cecchin E. Toffoli G, et al. Among authors: pella n. Int J Cancer. 2015 Dec 15;137(12):2971-80. doi: 10.1002/ijc.29654. Epub 2015 Jul 14. Int J Cancer. 2015. PMID: 26099996 Free article.
Immunotherapy for colorectal cancer: where are we heading?
Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G. Basile D, et al. Among authors: pella n. Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Expert Opin Biol Ther. 2017. PMID: 28375039 Free article. Review.
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S; Italian Group for the Study of Gastrointestinal Cancer (GISCAD); Scartozzi M. Giampieri R, et al. Among authors: pella n. Br J Cancer. 2017 Oct 10;117(8):1099-1104. doi: 10.1038/bjc.2017.234. Epub 2017 Sep 19. Br J Cancer. 2017. PMID: 28926529 Free PMC article. Clinical Trial.
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Ruzzo A, et al. Among authors: pella n. Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24. Br J Cancer. 2017. PMID: 29065426 Free PMC article. Clinical Trial.
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. Battaglin F, et al. Among authors: pella n. BMC Cancer. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x. BMC Cancer. 2018. PMID: 29370781 Free PMC article. Clinical Trial.
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators. Sobrero A, et al. Among authors: pella n. J Clin Oncol. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620994 Clinical Trial.
68 results